Peapack Gladstone Financial Corp Cuts Position in Abbott Laboratories $ABT

Peapack Gladstone Financial Corp trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 5.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 141,247 shares of the healthcare product maker’s stock after selling 8,374 shares during the period. Peapack Gladstone Financial Corp’s holdings in Abbott Laboratories were worth $17,697,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. American National Bank of Texas increased its stake in shares of Abbott Laboratories by 2.4% during the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after buying an additional 79 shares during the period. Nia Impact Advisors LLC increased its stake in shares of Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after buying an additional 79 shares during the period. Connable Office Inc. increased its stake in shares of Abbott Laboratories by 0.5% during the third quarter. Connable Office Inc. now owns 15,042 shares of the healthcare product maker’s stock worth $2,015,000 after buying an additional 81 shares during the period. Park Place Capital Corp increased its stake in shares of Abbott Laboratories by 11.0% during the fourth quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock worth $102,000 after buying an additional 81 shares during the period. Finally, Lantern Wealth Advisors LLC increased its stake in shares of Abbott Laboratories by 1.7% during the third quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock worth $674,000 after buying an additional 84 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott recently secured FDA and EU approval for its AI-powered Ultreon 3.0 tool, which could support growth in its cardiovascular imaging business and add to its medical technology momentum. Article Title
• Positive Sentiment: Abbott also obtained CE mark clearance for its Libre Duo glucose-ketone monitor, expanding its diabetes technology lineup and reinforcing innovation in one of its key growth categories. Article Title
• Neutral Sentiment: Recent coverage highlighting strong Wall Street views on Abbott suggests analysts remain constructive on the stock’s long-term prospects, but the articles do not point to a new upgrade or a near-term earnings catalyst. Article Title
• Neutral Sentiment: Zacks noted that investors have been searching for Abbott more heavily, which can reflect increased interest, but does not by itself change the company’s fundamentals. Article Title
• Negative Sentiment: One comparison piece argued Boston Scientific may offer more upside than Abbott, which can weigh on ABT sentiment by implying investors may prefer a rival medtech name right now. Article Title

Insider Buying and Selling

In related news, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a research note on Wednesday, April 22nd. Weiss Ratings cut Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, April 24th. Evercore decreased their target price on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Oppenheimer decreased their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, UBS Group decreased their target price on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $119.09.

Abbott Laboratories Trading Down 0.3%

NYSE:ABT opened at $85.36 on Monday. The firm has a market cap of $148.68 billion, a P/E ratio of 23.91, a PEG ratio of 1.43 and a beta of 0.63. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock’s 50 day simple moving average is $94.46 and its 200-day simple moving average is $110.58. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.